Literature DB >> 22443648

Current surgical therapy for stage IIIA (N2) non-small cell lung cancer.

Jane Yanagawa1, Valerie W Rusch.   

Abstract

Local therapy alone (surgery or radiation) leads to poor overall survival in patients with stage III non-small cell lung cancer because most of these patients die of distant metastases. During the past 20 years, studies have focused on developing effective chemotherapy regimens that can be combined with local therapies (surgery and/or radiation). The role of surgery has been evaluated, and the selection criteria for resection have been defined. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22443648     DOI: 10.1053/j.semtcvs.2011.12.001

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  2 in total

Review 1.  From Diagnosis to Treatment: Clinical Applications of Nanotechnology in Thoracic Surgery.

Authors:  Christopher S Digesu; Sophie C Hofferberth; Mark W Grinstaff; Yolonda L Colson
Journal:  Thorac Surg Clin       Date:  2016-05       Impact factor: 1.750

2.  Multimodality therapy in subclassified stage IIIA-N2 non-small cell lung cancer patients according to the Robinson classification: heterogeneity and management.

Authors:  Hans-Stefan Hofmann; Jan Braess; Susanne Leipelt; Michael Allgäuer; Monika Klinkhammer-Schalke; Tamas Szoeke; Christian Grosser; Michael Pfeifer; Michael Ried
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.